AllAnalyst Report
logoMorningstarAugust 30, 2020

BioNTech SE: Three COVID-19 Vaccines Capable of U.S. Authorization in 2020; Minimal Long-Term Valuation Impact

Current Price
Fair Value
Economic Moat

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab, and does not yet have any commercialized medicines.
Quotes from this report
SymbolNamePriceIndustryCurrencyMarket CapMorningstar RatingEconomic MoatUncertainty RatingFair ValuePrice/Fair Value

Analyst Profile

Anna Baran

Equity Analyst
Anna Baran is an equity analyst on the healthcare team for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc.Before joining Morningstar in 2016, Baran completed a research project in oncology at the Feinberg School of Medicine and another research thesis in neurobiology at Northwestern University. Before moving to her current role in February 2018, she was on the global and managed portfolios service teams at Morningstar.Baran holds a bachelor’s degree in economics and biological sciences from Northwestern University. She is also a Level II candidate in the Chartered Financial Analyst® program.